Baltimore Patient Pursued Hormone-Blocking Trial
Kayla Thompson opted for a clinical trial after a Stage 4 breast cancer diagnosis during pregnancy.
Updated on Oct. 12, 2026 in Cancer
On October 12, 2025, it was reported that 27-year-old Kayla Thompson managed her Stage 4 breast cancer through a clinical trial in Baltimore. After discovering a lump while seven months pregnant, she began using estrogen-blocking medication instead of traditional chemotherapy.
Why it matters
The case highlights an shift in care for hormone-receptor-positive breast cancer, where modern drugs provide more tolerable options than immediate chemotherapy. These advancements allow patients to maintain better quality of life while effectively managing the disease.
The clinical trial focuses on patients who are estrogen positive and HER2 negative, utilizing medication that has become available over the last 10 years. Treatment involves a regimen of oral medication or a combination of injections and oral drugs.
The players
Kayla Thompson
A patient who was diagnosed with Stage 4 breast cancer at age 27 while pregnant.
Mercy Medical Center
A Baltimore-based healthcare facility where the clinical trial treatment is being conducted.
The details
Thompson, who was diagnosed with lesions in her right breast and liver while pregnant, participates in the study at Mercy Medical Center. Her treatment protocol prioritizes hormone-blocking therapy to delay the necessity of chemotherapy.
Timeline
Over the last 10 years, new drug options for breast cancer have entered the market.
The clinical trial treatment began more than one year ago.
Health Landscape
This case reflects the broader evolution of oncology toward targeted therapies, specifically through the development of hormone-blocking therapies for estrogen-positive breast cancer. Such treatments move away from the historical reliance on aggressive chemotherapy for initial intervention.
Patients diagnosed with hormone-receptor-positive breast cancer may find that modern pharmacological interventions offer fewer side effects than conventional chemotherapy. Consult with an oncologist to determine if targeted hormone therapies are appropriate for your specific diagnostic profile.
The takeaway
Advancements in oncology have significantly expanded the treatment options available to those with hormone-positive breast cancer. Discussing all available clinical trial opportunities with a specialist can be vital for patients seeking alternative treatment pathways.
Further reading
Learn more about the latest developments in Cancer research and treatments.
Source note: This article includes information reported by WBAL.
